The treatment environment forever changed.

 

OPDIVO is a new class of programmed cell death protein (PD-1) inhibitors, or immune checkpoint inhibitors, that can block cancer-causing proteins from developing, and activate the patient’s own immune system to give them the power to fight cancer from within.

 

Nukleus worked with the OPDIVO team at Bristol Myers Squibb to explore a range of creative ideas like this final execution that starkly contrasts a bleak, long-dormant external treatment landscape with the lush greenery of a reactivated internal immune system—and powerfully signals the changing of the cancer treatment environment forever.